Tags: Cancer | keytruda | melanoma | drug | fda

FDA OKs New Drug to Combat Melanoma

Thursday, 04 Sep 2014 04:50 PM

 

Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments.
 
The Food and Drug Administration said it has granted accelerated approval to Merck's Keytruda, for treating melanoma that's spread or can't be surgically removed, in patients previously treated with another cancer drug.

The genetically engineered drug, known chemically as pembrolizumab, is part of a hot, promising new class of antibody-based drugs. They work by taking a brake off the immune system so it can better recognize and attack cancer cells.
 
Special: Prescription Drugs: Are You Taking Too Many?

"Ninety percent of patients have basically no side effects," Dr. Antoni Ribas, a UCLA researcher who was the lead investigator of a crucial study of Keytruda, told The Associated Press in an interview.

By comparison, most patients getting chemotherapy suffer with nausea, vomiting and hair loss.

In addition, Ribas said, Keytruda and other "immune-therapy" drugs appear likely to work against many more types of cancer than older drugs, and in a much higher percentage of patients. In a study of 600 patients, one-third of them benefited from the drug, with 62 percent of those alive after 18 months.

Chemotherapy drugs have an average survival of about nine months, while some newer cancer drugs on average keep patients alive for 11 to 15 months, he noted.

"This is just the start," Ribas said, adding that earlier tries at immune therapy for cancer typically helped only 5 to 10 percent of patients.

Merck's drug is the first in the class of what's called anti-PD-1 drugs approved in the U.S.
Bristol-Myers Squibb Co. and a partner have a drug similar to Keytruda, called Opdivo, that was approved in Japan in July. They are seeking U.S. approval for it.
 
Special: Prescription Drugs: Are You Taking Too Many?


© Copyright 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Top Trainer's Step-by-Step Plan for Better Fitness

Sunday, 25 Jan 2015 11:25 AM

The excitement and anticipation surrounding the upcoming Super Bowl may prompt some people to take up anew sport or up t . . .

Tide Turning in Ebola Fight After Hard Lessons

Saturday, 24 Jan 2015 15:16 PM

A top U.N. official in the fight against Ebola greeted just three patients at one treatment center he visited this week  . . .

'Miracle' Vaccine, Drugs Will Soon Stop AIDS: Bill Gates

Saturday, 24 Jan 2015 10:18 AM

Two new tools to fight AIDS should be available by 2030 in the form of a vaccine and new intense drug treatments, ending . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved